Abstract
Non-small cell lung cancer (NSCLC) is a leading cause of cancer related death worldwide. Late diagnosis and poor prognosis of advanced cancer are considered to be the main causes for the high mortality rates in NSCLC. Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD1) demonstrated substantial improvements in overall survival (OS) compared with chemotherapy in previously treated patients with advanced NSCLC. However, the annual therapy costs are high (>EUR100,000 in Germany).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
